test

Stephanie Halene MD, PhD

Assistant Professor of Medicine (Hematology)

Clinical Interests

Leukemia; myelodysplasia; myeloproliferative disorders; polycythemia; thrombocytosis; thrombocytopenia; sickle cell disease; thrombosis; coagulation


Board Certifications

2006
Hematology (Internal Medicine), Board Certified

Patient Care Locations

stephanie_halenefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Hematologic MalignanciesLongitudinal Assessment and Functional Outcomes in Patients with Hematologic Malignancies and Related Disorders
Myeloid and Monocytic LeukemiaA Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Myeloid and Monocytic LeukemiaE2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, not otherwise specified and Myeloid and Monocytic LeukemiaAn Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Leukemia, other(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

More Clinical Trials...

Edit Profile